HJM-561

Overview

HJM-561 is a selective and effective orally active EGFR PROTAC degrader. HJM-561 is able to overcome the triple EGFR mutations that are resistant to Osimertinib ( HY-15772 ). HJM-561 exhibits potent degradation of EGFR Del19/T790M/C797S ( DC 50 : 9.2 nM) and L858R/T790M/C797S ( DC 50 : 5.8 nM), and has anti-tumor activity (pink: EGFR ligand ( HY-12857 ); blue: CRBN ligand ( HY-A0003 ); black: linker).

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > PROTAC | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > JAK/STAT Signaling | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > PROTACs | Products > Signaling Pathways > EGFR

Product Information

• Catalog No.: HY-156698
• CAS No.: 2570251-68-0
• Molecular Formula: C45H51ClN9O5P
• Molecular Weight: 864.37
• Purity: 99.26%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (2.89 mM); Clear solution
• Availability: In-stock

Source

Original product source